New eczema ointment enters first human tests
NCT ID NCT06744569
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new ointment called CU-10101 in 64 people, first in healthy volunteers and then in those with mild to moderate atopic dermatitis (eczema). The main goal is to check safety and how the body handles the drug, with a preliminary look at whether it improves skin symptoms. The study is small and not designed to prove effectiveness yet.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CU-10101 ointment
- What this could lead to
- If it works, this could point toward a new topical treatment to ease symptoms of atopic dermatitis (eczema).
- What could go wrong
- This is a very early Phase 1 trial with only 64 participants, focused on safety. It is too small and early to know if the ointment actually helps eczema, and it may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Skin Disease Hospital
Shanghai, Shanghai Municipality, 200433, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?